Congress Asset Management Co. Buys 1,454 Shares of Eli Lilly and Company $LLY

Congress Asset Management Co. increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% during the 3rd quarter, Holdings Channel.com reports. The firm owned 124,514 shares of the company’s stock after acquiring an additional 1,454 shares during the quarter. Eli Lilly and Company comprises about 0.9% of Congress Asset Management Co.’s holdings, making the stock its 23rd largest position. Congress Asset Management Co.’s holdings in Eli Lilly and Company were worth $144,073,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the stock. Osbon Capital Management LLC bought a new position in Eli Lilly and Company in the 4th quarter valued at $25,000. Basso Capital Management L.P. bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $30,000. Maseco LLP lifted its stake in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares during the period. Aventus Investment Advisors Inc. lifted its stake in shares of Eli Lilly and Company by 270.0% during the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after acquiring an additional 27 shares during the period. Finally, Marshall & Sterling Wealth Advisors Inc. boosted its holdings in Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after acquiring an additional 15 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 in the last ninety days. Company insiders own 0.14% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on LLY shares. Morgan Stanley reiterated an “overweight” rating and issued a $1,419.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 6th. TD Cowen reaffirmed a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Citigroup boosted their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Finally, HSBC increased their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,311.96.

Eli Lilly and Company Trading Up 1.3%

NYSE LLY traded up $14.49 on Tuesday, reaching $1,157.61. The company had a trading volume of 2,130,131 shares, compared to its average volume of 2,977,802. The stock’s 50 day moving average is $1,175.28 and its 200-day moving average is $1,090.99. The stock has a market cap of $1.09 trillion, a price-to-earnings ratio of 38.85, a PEG ratio of 1.40 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 52 week low of $783.85 and a 52 week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the prior year, the firm posted $6.31 earnings per share. The company’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts predict that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA expanded approval of Jaypirca for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma patients without a 17p deletion. The decision, supported by Phase 3 data, could expand the drug’s addressable market and strengthen Lilly’s oncology growth. FDA expands Eli Lilly’s blood cancer drug label
• Positive Sentiment: Lilly’s experimental cancer drug olomorasib received FDA orphan-drug designation for pancreatic cancer. The status may provide development incentives and potential market exclusivity, reinforcing Lilly’s strategy to diversify beyond GLP-1 medicines. Lilly expands oncology footprint
• Positive Sentiment: New analysis presented at the European Association for the Study of Diabetes meeting showed Lilly’s oral GLP-1 candidate Foundayo produced greater weight loss and better blood-sugar control than oral semaglutide 25 mg in adults with type 2 diabetes. If confirmed in later-stage studies and commercialized successfully, the pill could extend Lilly’s metabolic-health leadership. Foundayo analysis versus oral semaglutide
• Positive Sentiment: Lilly expanded its collaboration with Gate Bioscience in a potential agreement worth more than $870 million, while also making its insitro-developed machine-learning models available through Lilly TuneLab. These deals could improve future drug discovery and add longer-term pipeline value. Lilly expands Gate Bioscience collaboration
• Neutral Sentiment: Early-stage updates for Lilly’s elt­re­kibart antibody and a new basal-insulin candidate indicate continued pipeline progress, but Phase 1 results do not yet establish commercial viability. Lilly also plans 21 dermatology presentations, potentially providing additional catalysts later this month.
• Negative Sentiment: Analysts and commentators cautioned that LLY’s valuation—roughly 38 times earnings, well above the broader market—already reflects very high growth expectations. Any slowdown in Zepbound or Mounjaro demand, pricing pressure, trial setbacks or regulatory delays could leave limited room for error. Eli Lilly valuation risk

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.